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 38 
Abstract 39 
Background: 40 
Adverse Drug Reactions (ADRs) are a major clinical and public health problem world-wide.  The 41 
prompt reporting of suspected ADRs to regulatory authorities to activate drug safety surveillance 42 
and regulation appears to be the most pragmatic measure for addressing the problem. This paper 43 
evaluated a pharmacovigilance (PV) training model that was designed to improve the reporting of 44 
ADRs in public health programs treating the Human Immunodeficiency Virus (HIV), Tuberculosis 45 
(TB) and Malaria. 46 
Methods: 47 
A Structured Pharmacovigilance and Training Initiative (SPHAR-TI) model based on the World 48 
Health Organization accredited Structured Operational Research and Training Initiative (SOR-IT) 49 
model was designed and implemented over a period of 12 months. A prospective cohort design 50 
was deployed to evaluate the outcomes of the model. The primary outcomes were knowledge 51 
gained and Individual Case Safety Reports (ICSR) (completed adverse drug reactions monitoring 52 
forms) submitted, while the secondary outcomes were facility-based Pharmacovigilance 53 
Committees activated and health facility healthcare workers trained by the participants.   54 
Results: 55 
Fifty-five (98%) participants were trained and followed up for 12 months. More than three quarter 56 
of the participants have never received training on pharmacovigilance prior to the course. Yet, a 57 
significant gain in knowledge was observed after the participants completed a comprehensive 58 
training for six days. In only seven months, 3000 ICSRs (with 100% completeness) were 59 
submitted, 2,937 facility-based healthcare workers trained, and 46 Pharmacovigilance Committees 60 
activated by the participants. Overall, a 273% increase in ICSRs submission to the National 61 
Agency for Food and Drug Administration and Control (NAFDAC) was observed. 62 
Conclusion:  63 
Participants gained knowledge, which tended to increase the reporting of ADRs. The SPHAR-TI 64 
model could be an option for strengthening the continuous reporting of ADRs in public health 65 
programs in resource limited settings.  66 
 67 
 68 
 69 
 70 
 71 
1. Background 72 
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Adverse Drug Reactions (ADR) have emerged as a major clinical and public health problem 73 
accounting for approximately 5 to 35% of hospital admissions in both developed and developing 74 
countries [1-7].  In the United States and Europe, ADRs are also the leading causes of mortality 75 
[4, 8, 9 and 10]. In African countries, the introduction of ART has led to an upsurge in the cardio-76 
metabolic disorders such as type 2 diabetes mellitus and hypertension. Some authors have provided 77 
evidence linking the use of the ARVs to the cardio-metabolic disorders [11, 12]. Similarly, 78 
treatment of drug resistant tuberculosis is contributing to the incidences of mental illnesses 79 
(psychosis), loss of hearing (ototoxicity) and   kidney damage – all associated with the ADRs of 80 
second line anti-tuberculosis drugs [13].  81 
Under-reporting of ADRs is a major challenge even in developed countries with adequate human 82 
and material resources to tackle the problem [4, 8, 9 and 10].  A systematic review of 37 studies 83 
by Hazell and Shakir found a median under-reporting rate of 94% [14]. There are many factors 84 
associated with the under-reporting of ADRs [15]. The commonest factors frequently cited in most 85 
of the studies are healthcare workers’ lack of knowledge and poor attitude [16-29]. In a very recent 86 
study by Terblanche et al [30] found that 53.8% of the participants gave not “knowing how to 87 
report” ADR as the reason discouraging the reporting. Interestingly, some studies have shown that 88 
training could address the lack of knowledge and increase the accuracy and rate of reporting of 89 
ADRs to regulatory bodies [14, 31].  90 
Prompt reporting of ADRs to regulatory bodies to activate drug safety surveillance and regulation 91 
is the most pragmatic and cost-effective public health approach to addressing the risks of ADRs 92 
and ensuring public health [32].  The delay in reporting ADRs can be catastrophic. For example, 93 
almost seven million patients took Fenfluramine before its association with Valvular Heart Disease 94 
(VHD) was reported and the drug withdrawn from the market [33]. Similarly, over 10,000 children 95 
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in Germany in the early sixties had suffered Phocomelia before Thalidomide – the causative agent, 96 
was identified and withdrawn from clinical practice [34]. 97 
In the public health programs, especially the HIV, Tuberculosis and Malaria programs, millions of 98 
people are treated with a wide range of drugs, some of which have serious/life threatening adverse 99 
reactions [35-38].  In the western countries where anti-retroviral drugs (ARVs) have been used for 100 
many years, cases of rising obesity, weight gain and cardio-metabolic diseases are persistently 101 
being reported in association with the use of ARVs [39-40]. Drug safety is therefore a serious 102 
concern, especially in the public health programs treating large populations of people with 103 
potentially life-threatening drugs. 104 
1.2.The pharmacovigilance system in Nigeria 105 
Pharmacovigilance systems (PVS) refer to schemes that are established to facilitate the reporting 106 
of suspected ADRs to national or international body responsible for the monitoring of drug safety 107 
and regulations.  Countries participating in the international drug monitoring scheme are required 108 
to collect and submit their reports to the International Drug Monitoring Center in Geneva. 109 
Nigeria joined the International Drug Monitoring Scheme in 2004 and became the 74th member 110 
country. The National Agency for Food and Drug Administration and Control (NAFDAC) – the 111 
body responsible for drug safety and regulation, thereafter, developed a National 112 
Pharmacovigilance Policy and instituted an administrative structure, consisting of the National 113 
Pharmacovigilance Center (NPC) in Abuja and Zonal Pharmacovigilance Centers (ZPC) in each 114 
of the six geopolitical regions of the country. 115 
NAFDAC also instituted the National Pharmacovigilance System which involves signal detection, 116 
collection, collation and analysis of ADRs [41]. Organizations or individuals holding a marketing 117 
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authorization for marketing medicinal products are mandated to report any suspected ADR 118 
associated with the product they are authorized to market [41]. Healthcare providers (pharmacists, 119 
doctors and nurses) are also required by the government to report suspected ADRs, although this 120 
is not mandatory [41] as is the case in Sweden, France and Italy [42].  121 
The primary tool for reporting ADRs in Nigeria is a structured in-take form known as the 122 
“NAFDAC Yellow Form” or “ADR Form” (https://www.nafdac.gov.ng) [Additional File 1; 123 
Figure 2]. This form is similar to the United Kingdom’s Yellow Card and has five major sections, 124 
which must all be accurately completed. A fully completed ADR form is known as the “Individual 125 
Case Safety Report” (ICSR). 126 
The quality of an ICSR is directly proportional to the amount of clinically relevant information 127 
that is included [43-46]. On this basis, an ICSR with 100% completeness is expected to have the 128 
highest quality provided that the information included in all the sections is accurate. Poor quality 129 
ICSRs are usually quarantined by the NPC as they cannot be sent to the International Drug 130 
Monitoring Center in Uppsala, Sweden. 131 
A typical ICSR provides the following information: 132 
a. Patient details (name, age, sex and weight) 133 
b. Adverse drug reaction (description, date reaction started and stopped and outcome – 134 
recovered fully, congenital abnormality, recovered with abnormality, life threatening and 135 
death) 136 
c. Suspected drug (brand and generic names, batch number, NAFDAC number, expiry date) 137 
d. Concomitant medicines (all medicines taken in the last three months) 138 
e. Source of report 139 
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The reporting of ADRs in Nigeria follows two major steps:  140 
a. Accurate completion of the ADR forms when a suspected ADR is observed by healthcare 141 
providers or reported by a patient during routine treatment of health conditions. Marketing 142 
Authorization Holders (MAH) are also expected to complete the ADR forms when 143 
suspected ADR are reported to them by patients, health institutions or the healthcare 144 
workers within and outside the country. 145 
b. Dispatch the ICSRs to the NPC in Abuja.  146 
The ICSRs are dispatched to the NPC in Abuja through different means. The responsibility of the 147 
NPC is to validate and analyze the submitted ICSRs and extract the relevant information into 148 
VigiBase – a proprietary web database (https://www.who-umc.org/vigibase/vigibase/) hosted at 149 
the World Health Organization (WHO) collaborating center for international drug monitoring in 150 
Uppsala, Sweden. 151 
1.3. The pervasive problem of under-reporting of adverse drug reactions in Nigeria 152 
 The under-reporting of ADRs in Nigeria has been documented in several studies [47-50]. 153 
According to NAFDAC, only 16,500 ICSRs out of 80,000 uncompleted ADR forms distributed 154 
nation-wide for 12 years (2004 to 2016), equivalent to 1,375 ICSRs per year were submitted back 155 
to NAFDAC [51]. The WHO criteria for adequate reporting of ADRs are 200 reports per million 156 
inhabitants per year [52]. With a population of 170 million inhabitants in 2016, at least 34,000 157 
ICSRs should have been submitted to NAFDAC instead of the 1,375 ICSRs. Furthermore, Nigeria 158 
had 323,941healthcare workers [53-54] (consisting of Physicians, Nurses, Midwives, Pharmacists, 159 
Pharmacy-technicians, Radiographers, Medical Laboratory Scientists and Community Health 160 
Officers), [55-56] according to the 2005-2007 report of the National Professional Medical/Health 161 
Regulatory bodies. In 2015, NAFDAC reported that only 1,385 ICSRs [Additional File 2: figure 162 
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S1] were submitted by over 323,941 workers.  Given the large population of healthcare workers 163 
and the overwhelming increase in drug consumption due to the high burden of HIV/AIDS, 164 
Tuberculosis and Malaria, submitting only 1,385 ICSRs clearly indicates that Nigeria is facing a 165 
major crisis of under-reporting of ADRs.  Ironically, the factors that are undermining the reporting 166 
of ADRs in other countries are rife in Nigeria and these include lack of knowledge, inaccurate 167 
description of ADRs, poor quality reports and poor compliance to the pharmacovigilance processes 168 
(data collection, storage, management, risk assessment and communication) [14,41,44].  169 
The SPHAR-TI model was designed to address the challenge of under-reporting of ADR through 170 
capacity building. Until the SPHAR-TI course, majority (71.0%) of the participants in the study 171 
have never received training in pharmacovigilance but were working in public health institutions 172 
or hospitals directly treating HIV/AIDS, Tuberculosis and Malaria through the respective public 173 
health disease control programs. Some studies have reported high prevalence of ADRs emanating 174 
from these public health programs [13, 35, 37, 38, 39, 40], thus, justifying the SPHARTI model. 175 
1.4.The SPHAR-TI model 176 
The SPHAR-TI model – described under “Additional File 2”, was a 12 month modular course, 177 
modelled after the WHO accredited Structured Operational and Training Initiative (SOR-TI) 178 
[57,58] The model incorporated six distinct but inter-related activities, referred to as the SPHAR-179 
TI’s principles. These are: a training workshop; participants’ mobilization; monitoring and 180 
evaluating and providing feedback; setting up a reporting system; providing leadership and 181 
collaborating with the government.  This paper evaluated the model with the main objective of 182 
describing its outcomes. 183 
2. Methods 184 
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This manuscript complies with the STROBE reporting standard for observational studies. 185 
2.1. Ethics approval 186 
 Ethics approval was given by the National Health Research Ethics Committee of Nigeria under 187 
the title: “Engaging indigenous organization to sustain and enhance clinical services for the 188 
prevention, care and treatment of HIV/AIDS in the Federal Republic of Nigeria under the 189 
President’s Emergency Plan for AIDS Relief (PEPFAR)”; Number: NHREC/01/01/2007; dated 190 
August 12, 2016. The Institute of Human Virology Nigeria, headed by Dr. Patrick Dakum, 191 
obtained this ethics clearance for all the studies conducted under its mentor-ship.  192 
2.2. Setting 193 
 Selected health facilities and institutions in the six geopolitical regions of Nigeria constituted the 194 
setting. Nigeria has six geopolitical regions with a population of 170 million inhabitants. These 195 
regions include North-east, North-west, North-central, South-west, South-east and South-south. 196 
2.3. Study population 197 
The study population consisted of health care workers (Nurses, Physicians and Pharmacists) who 198 
were selected for the SPHAR-TI course based on rigorous selection criteria itemized in Table 1.    199 
Table 1: Participants’ selection criteria for the SPHAR-TI model 200 
 201 
2.4. Study design 202 
A prospective cohort design was deployed for the evaluation of the SPHAR-TI model. Participants 203 
that attended the SPHAR-TI’s workshop (see Additional File 2) were followed up for 12 months 204 
through internet and telephone communication. Performance was evaluated based on the meetings 205 
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of milestones. Bio-demographic characteristics were recorded, and participants’ knowledge 206 
assessed at baseline. Five days after the workshop, participants’ knowledge was re-assessed 207 
without giving them a prior warning they would be re-assessed.  ICSRs were submitted online 208 
every three months (31st May, 29th July, 30th September and 30th November 2016). The number of 209 
healthcare workers trained by the participants and the Pharmacovigilance Committees activated 210 
were also submitted online not later than 10th December 2016.   211 
2.5. Outcomes of measure 212 
The aim of the model was to improve the reporting of ADRs from both hospitals based and more 213 
importantly, community based public health programs controlling the AIDS epidemic, 214 
Tuberculosis and Malaria. The primary outcomes were knowledge gained and the number of 215 
ICSRs submitted to NAFDAC. We expected to see a significant gain in knowledge and a 216 
remarkable increase in the reporting of ADRs if the model is effective. The secondary outcomes 217 
were the health facility staff trained by the participants through the step-down training and the 218 
Pharmacovigilance Committees activated.  219 
The secondary outcomes were evaluated because NAFDAC encourages the setting up of 220 
Pharmacovigilance Committees in health facilities as a pragmatic strategy for promoting the 221 
reporting of ADRs. During the workshop, participants were taught and encouraged to step-down 222 
the workshop and activate the committees. We expected the participants to be able to train others 223 
and set up new Pharmacovigilance Committees if the model is effective. 224 
2.6. Evaluation of the outcomes of the model 225 
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The overall outcome of the model was assessed by comparing the number of ICSRs submitted by 226 
the national health workforce in seven months with the number submitted by the participants in 227 
seven months. The primary and secondary outcomes were evaluated as described below: 228 
2.6.1. Gain in knowledge  229 
Gain in knowledge was assessed using a structured questionnaire, consisting of 24 questions 230 
developed by expert physicians and pharmacists in the three diseases (HIV, TB and Malaria). The 231 
questions covered the clinical management of HIV/AIDS, Tuberculosis and Malaria and the ADRs 232 
associated with the use of antiretroviral, anti-tuberculosis and anti-malaria drugs. The 233 
questionnaire also assessed the knowledge of Nigeria’s ADR reporting and pharmacovigilance 234 
system.  235 
Prior to the commencement of the workshop, the questionnaire was administered for an hour (pre-236 
test).  At the end of the workshop, which was five days after the pre-test, the same questionnaire 237 
was re-administered (post-test). To minimize measurement biases, the questionnaire was 238 
withdrawn immediately after the pre-test and participants were not warned the questionnaire would 239 
be re-administered after the workshop.  Participants did not also know the result of the pre-test 240 
until after the post-test. The pass mark for the pre and post-tests was 45%. 241 
 242 
2.6.2. Individual case safety reports submission 243 
The correctness and completeness of the ICSR and the quantities submitted online were assessed. 244 
All submitted ICSRs were manually checked for correctness and completeness and the total 245 
number of correctly completed forms were counted and recorded in each cycle. We summed up 246 
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the number of ICSRs submitted within seven months and compared it with the amount that would 247 
have been submitted by the national health workforce in seven months in 2015. 248 
2.6.3. Pharmacovigilance committees activated and training of health facility staff by 249 
participants 250 
To assess the two variables, participants were given a spreadsheet for recording their activities 251 
after the workshop. The spreadsheet included the following variables: 252 
(a). Status of the health facility 253 
(b). Date of training 254 
(c). Description of training 255 
(d). Objectives of the training 256 
(e). Mode of delivery of training content 257 
(f). Number of doctors, nurses and pharmacists in attendance 258 
(g). Number of Pharmacovigilance Committees activated 259 
(h). Involvement of hospital management 260 
(i). Collaboration with a pharmaceutical company in the training 261 
(j). Collaboration with NAFDAC. 262 
The completed spreadsheets were submitted to NAFDAC online at different times but not later 263 
than 10th December 2016. We extracted the number of health facility staff trained and the number 264 
of Pharmacovigilance Committees’ activated into a template for analysis. 265 
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2.5.4. Statistical analysis 266 
We applied descriptive statistics (mean, percentage and summation) in the analysis of the bio-267 
demographic data and primary and secondary outcomes. The overall outcome of the model was 268 
analyzed by calculating the percentage increase in ADR submission using the arithmetic formula: 269 
T-M/M*100 [Where T = total number of ICSRs submitted by the participants in seven months; M 270 
= total number of ICSR submitted by the national health workforce in seven months]. According 271 
to NAFDAC, in 2015, the over 323,941 national health workforces submitted 1,385 ICSRs 272 
[Additional File 1), equivalents to 805 ICSRs in seven months. The 3000 ICSRs (T) and 805 ICSRs 273 
(M) were plucked into the arithmetic formula to determine the percentage increase in ICSRs 274 
submission. 275 
Participants gain in knowledge was analyzed by calculating the difference between the mean pre-276 
test and post-test scores. Summation was applied in analyzing the number of ICSR submitted by 277 
the participants, health staff trained by the participants and Pharmacovigilance Committees 278 
activated. 279 
3. Results 280 
Participants’ characteristics are presented in Table 2. Fifty-five out of 56 participants attended the 281 
workshop and were trained, equivalent to 98.2% attendance rate. Participants without a previous 282 
training in pharmacovigilance were more than participants that have attended pharmacovigilance 283 
training (s) in the past [39(71%) vs 16 (29.1%)]. 284 
Table 2: Participants’ characteristics, N = 55 285 
Table 3 compares the difference in the mean scores (gain in knowledge) among the participants. 286 
It appears participants >40 years [9.4 (SD=7.0], Pharmacists [8.5 (SD= 7.4)], and Nurses [7.6 287 
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(SD=6.4], participants treating malaria [9.3 (SD=8.8] and those without previous training [9.5 288 
(SD=7.8)], had remarkable gain in knowledge after the workshop. 289 
Table 3: Association between post test scores and participants’ characteristics 290 
The outcomes of the model are presented in Table 4. Participants demonstrated a significant gain 291 
in knowledge (20.4 vs 27.8 (P value < 0.001) and submitted 3000 ICSRs with 100% correctness 292 
and completeness. Compared with the 805 ICSRs submitted by more than 323,941 healthcare 293 
workers in the general population who were not SPHAR-TI trained, the percentage increase in 294 
ICSRs submission was 273%. Participants were also able to independently train 2,937 healthcare 295 
workers and activated 46 Pharmacovigilance Committees. 296 
Table 4: The outcome of the SPHAR-TI model 297 
 298 
 299 
 300 
 301 
 302 
 303 
 304 
4. Discussion 305 
The major finding of this evaluation is the significant gain in knowledge observed among the 306 
participants generally. NAFDAC’s concordance on the effectiveness of the model to significantly 307 
improve the reporting of ADRs in Nigeria [Additional file 1: Figure S1] buttresses this observation 308 
and underscores the potential viability of the model to improve the reporting of ADRs in public 309 
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health programs. Furthermore, the positive outcome achieved when NAFDAC tested the model in 310 
the training of 600 healthcare workers from ten states in Nigeria [Additional file 1: Figure S1], 311 
suggests that the model can be replicated in countries facing similar challenge of under-reporting 312 
of ADRs with Nigeria.  313 
We also observed four additional outcomes. Firstly, participants developed the capacity to detect 314 
and accurately report ADRs including the serious ADRs such as Stevens Johnson Syndrome (SJS). 315 
Secondly, the rate of ADR reporting increased by 273%, when compared with the average 316 
reporting rate in the general population over the past 12 years. This finding is consistent with the 317 
findings from previous studies that examined the impact of training aimed at improving the 318 
reporting of ADRs [31, 59]. Thirdly, participants were able to train their peers, thus, they increased 319 
the number of healthcare workers for pharmacovigilance service delivery particularly in the 320 
communities. In addition, participants developed the capacity to activate Pharmacovigilance 321 
Committees in their various health facilities. This is a feat NAFDAC has persistently encouraged 322 
in an effort to boost the reporting of ADRs in Nigeria. 323 
We also observed two unintended outcomes of the application of the SPHAR-TI’s model. The first 324 
is the detection and reporting of SJS by many participants. SJS is a fatal ADR associated with the 325 
use of Nevirapine, a popular antiretroviral drug that constitutes the backbone of first line 326 
antiretroviral regimen. This finding assures us that Nigerians are also susceptible to the ADR of 327 
Nevirapine as reported in other climes. Further analysis of the submitted ICSRs might reveal other 328 
life threatening ADRs in the Nigerian population, which the National Agency for the Control of 329 
AIDS (NACA) need to pay close attention to. The second outcome is the interplay of several 330 
factors resulting in an increase in the reporting of ADRs. The model combined at least six factors; 331 
there is no gainsaying in concluding that training alone without the other factors could not have 332 
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yielded the results we have reported. Perhaps, the reason Nigeria and other countries are not able 333 
to significantly address the challenge of under-reporting of ADRs despite the abundance of training 334 
may be the over-reliance on training without combining the other factors. 335 
We observed a surprised finding in the evaluation (table 3). Participants without prior training 336 
tended to gain knowledge more than those who have attended pharmacovigilance trainings. The 337 
same tendency was observed among the health care workers, with pharmacists and nurses gaining 338 
knowledge more than the medical doctors. We do not have a viable reason for this but we suspect 339 
that personal commitment and seriousness may have led to the difference. Participants without 340 
prior training and the other healthcare workers were more committed to learning than the medical 341 
doctors who presumed they already knew the content of the course. 342 
The model holds an important lesson for sub-Saharan Africa (SSA), which has the largest public 343 
health programs treating millions of people with HIV, Tuberculosis and Malaria. Currently, over 344 
20 million people must be placed on antiretroviral drugs according to the new WHO treatment 345 
guidelines for HIV [60].  The risk of “antiretroviral therapy associated ADRs” is expected to be 346 
higher in this region than any other region in the world. Evidence from studies  conducted in 347 
developed countries where antiretroviral therapy has been offered for many years have  reported a 348 
rise of cardiometabolic disorders like type 2 diabetis mellitus and cardiovascular disease [61-65] , 349 
which have long been associated with  the antiretroviral medications. In the Drug Resistant 350 
Tuberculosis public health program, hearing loss associated with the use of the injectable 351 
aminiglycosides (Amikacin and Kanamycin) is a major clinical challenge [66-67]  and yet, 352 
thousands of patients are using these drugs in the communities.  As sub-Saharan African countries 353 
continue to scale-up public health treatment programs  in a wider global effort to end HIV and 354 
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Tuberculosis, the prevalence of ADRs will continue to increase, justifying the need for the training 355 
of healthcare providers for ADRs reporting.  356 
Another factor that favors the training of healthcare providers for ADR reporting, which justifies 357 
the use of the SPHAR-TI model, is the acute shortage of healthcare workers in Africa. The “Brain 358 
Drain” report by Rebecca Coombes showed that the number of healthcare workers in many African 359 
countries is shrinking [68]. Ghana with a population of 20 million has only 1500 medical doctors 360 
and more than two-third of young Ghanaian doctors leave the country within three years of 361 
graduation. In Mozambique, a nation of similar size with Ghana, there are only 500 medical 362 
doctors [68]. Malawi has a worse situation; there are 12 million people but only 350 medical 363 
doctors are available to cater for all the health needs including the reporting of ADRs [68]. Nigeria 364 
appears to have the highest density of healthcare workers in Africa [37-54] but the large population 365 
size and the lack of capacity for reporting ADRs are major constrains. However, the training of 366 
healthcare workers as has been shown in several studies can improve the reporting of ADRs. The 367 
WHO in its 2013 report on “research for universal health coverage”, highlighted the need for 368 
training of healthcare workers in public health programs close to the supply and demand side of 369 
health services [69]. The structured pharmacovigilance capacity building model that we have 370 
evaluated addresses this gap in response to the WHO recommendation.  371 
An important piece of information the SPHAR-TI model has demonstrated is that short training 372 
alone is not sufficient to stem the tide of under-reporting of ADRs. In fact, most developing 373 
countries, including Nigeria, provide trainings to healthcare workers to boost the reporting of 374 
ADRs but the crisis of under-reporting is not going away. What may be lacking are some of the 375 
factors the SPHAR-TI model has identified, which include: poor mobilization of healthcare 376 
providers, a weak monitoring and evaluation with complete absence of feedback mechanisms 377 
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when ICSRs are submitted to central regulatory authorities, lack of a clear and practical means of 378 
submitting ICSRs, lack of private-public collaboration, weak leadership and low motivation of the 379 
workforce. If all these factors are combined appropriately, the reporting of ADRs could 380 
significantly increase.  381 
The model has some limitations that need to be considered alongside the positive outcomes. Our 382 
participants were practicing doctors, nurses and pharmacists with some experience in the 383 
pharmacotherapy of AIDS, tuberculosis and malaria. This knowledge may have contributed to the 384 
knowledge gained through the SPHAR-TI training. This argument may however not hold true 385 
because the medical doctors who are expected to have come to the training with the highest level 386 
of knowledge and should have demonstrated higher scores compared to the pharmacists and nurses 387 
actually scored less. The age of the participants is another factor; majority of the participants were 388 
mid-career professionals occupying lower positions of responsibilities and were likely to be less 389 
busy and quick learners. Elderly people with many social and professional responsibilities and 390 
perhaps with a “slow to learn” disposition would probably have performed poorly. But again, the 391 
results in table 3 demonstrate that participant over 40 years scored higher marks than the younger 392 
people within the age bracket of 30-39 years. Overall, the long term impact of the model need  to 393 
be assessed; our findings in this study are only limited to the period of evaluation, which is between 394 
10 to 12 months. However, despite these limitations, the model has provided an option for 395 
improving the reporting of ADRs in resource limited settings. 396 
We are recommending the use of the SPHAR-TI’s model to minimize the worrisome under-397 
reporting of ADRs in the developing world. As stated earlier, under-reporting of ADRs prevents 398 
drug safety monitoring and regulation, which adds to the disease burden and mortality. Nigeria 399 
and other developing countries may not be able to absorb additional health challenges caused by 400 
18 | P a g e  
 
ADRs as these countries are already overstretched by communicable and non-communicable 401 
diseases. The SPHAR-TI model may be an effective approach that would complement existing 402 
models of ADRs reporting in Africa and elsewhere.  403 
Conclusion 404 
The systematic and output driven training and follow-up of healthcare providers had a positive 405 
impact on the reporting of ADRs. The SPHAR-TI principles effectively contributed to the success 406 
of the model and are recommended to institutions or organizations providing pharmacovigilance 407 
services in Africa and other regions with similar settings.  408 
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FIGURE LEGENDS AND TABLES 633 
FIGURE LEGENDS 634 
Additional file 1:  635 
Figure S1: A letter from the National Agency for Food and Drug Administration and Control 636 
appreciating the Institute of Human Virology Nigeria for increasing the reporting of adverse drug 637 
reactions through the Structured Pharmacovigilance and Training Initiative. 638 
Figure S2: Adverse drug reactions monitoring form (NAFDAC Yellow Form or ADR Form) 639 
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Additional file 2: Protocol of the Structured Pharmacovigilance and Training Initiative 640 
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TABLES 658 
Table 1: Participants’ selection criteria for the SPHAR-TI model 659 
1 Full time employee of a public health facility (non-profit health facilities that are opened to 
the public such as government or faith-based health institutions) providing Anti-retroviral 
Therapy (ART), Directly Observed Therapy (DOTS) and Roll Back Malaria (RBM) services 
2 Directly involved in the treatment of HIV/AIDs, TB or Malaria under the ART, DOTS and 
RBM programs 
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3 
 
Early or mid-career men and women with limited administrative responsibilities in the 
facility.  
4 Pharmacovigilance naïve (i.e. have never been trained on Pharmacovigilance) or only 
received partial training in pharmacovigilance 
5 A written Letter of Commitment to attend the workshop and also complete the monitoring 
and evaluation. 
6 One reference letter attesting to the candidate’s suitability and potential to complete the 
course 
7 Graduate or professional qualification or, strong recommendation by the public health 
program or work-place institution 
8 Computer literacy and proven competence in the language of instruction (English)  
 660 
 661 
 662 
 663 
 664 
 665 
 666 
 667 
 668 
Table 2: Participants’ characteristics, N = 55 669 
Characteristics N (%) 
Age 
   <30 years 
   30-39 years 
   40+ years 
 
5 (9.1%) 
29 (52.7%) 
21 (38.2%) 
Gender  
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   Female 
   Male 
24 (43.6%) 
31 (56.4%) 
Profession 
  Doctors 
  Pharmacists 
  Nurses 
 
11 (20.0%) 
34 (61.8%) 
10 (18.2%) 
Disease area 
  HIV/AIDS 
  Tuberculosis 
  Malaria 
 
39 (70.9%) 
10 (18.2%) 
6 (10.9%) 
Previous training 
   No 
   Yes 
 
39 (70.9%) 
16 (29.1%) 
Geopolitical Region 
   North-Central 
   North-West 
   North-East 
   South-West 
   South-East 
   South-South 
 
16 (29.1%) 
3 (5.6%) 
7 (12.7%) 
25 (45.6%) 
2 (3.6%) 
2 (3.6%) 
Table 3: Association between post test scores and participants’ characteristics 670 
Characteristics N (%) Difference score 
Mean (SD) 
Pvalue 
Age 
   <30 years 
   30-39 years 
   40+ years 
 
5 (9.1%) 
29 (52.7%) 
21 (38.2%) 
 
7.0 (2.7) 
6.0 (7.3) 
9.4 (7.0) 
 
0.16 
Gender 
   Female 
   Male 
 
24 (43.6%) 
31 (56.4%) 
 
7.5 (7.7) 
7.3 (6.5) 
 
0.96 
Profession    
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  Doctors 
  Pharmacists 
  Nurses 
11 (20.0%) 
34 (61.8%) 
10 (18.2%) 
3.6 (4.7) 
8.5 (7.4) 
7.6 (6.4) 
0.11 
Disease area 
  HIV/AIDS 
  Tuberculosis 
  Malaria 
 
39 (70.9%) 
10 (18.2%) 
6 (10.9%) 
 
8.2 (6.9) 
3.0 (4.5) 
9.3 (8.8) 
 
0.09 
Previous training 
   No 
   Yes 
 
39 (70.9%) 
16 (29.1%) 
 
6.5 (6.5) 
9.5 (7.8) 
 
0.21 
 671 
 672 
 673 
 674 
 675 
 676 
 677 
 678 
 679 
 680 
 681 
Table 4: The outcomes of the SPHAR-TI model 682 
DESCRIPTION Number (P-value) 
 
PARTICIPANTS TRAINED1: Participants trained at workshop 
vs Healthcare workers trained by participants after the 
workshop 
 
  
55 vs 2937 
KNOWLEDGE GAIN2: Mean pre vs post test scores 
 
20.4 vs 27.8 (P value< 
0.001) 
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ADRs REPORTED3: ADR reported by SPHAR-TI trained 
participants vs ADR reported by Healthcare providers in the 
general population) 
 
3000 ICSRs vs 805 ICSRs  
(percentage increase in ADR 
reporting =273%) 
PHARMACOVIGILANCE COMMITTEES4 : 
Pharmacovigilance Committees activated by SPHAR-TI 
participants before the workshop vs Pharmacovigilance 
committees activated by participants after the workshop 
0 vs 46 
NOTES:                                                                                                                                                                                                            683 
1 = The number of participants trained at the workshop are compared with the number of 684 
healthcare workers trained by the participants after the workshop (55 vs 2937).                                                                                                                             685 
2 = The mean pre and post test scores (20.4 vs 27.8) are compared; the difference between the 686 
two scores is statistically significant suggesting knowledge gained.                                                                                                                                                                         687 
3 = The number of ICSRs submitted to the National Agency for Food and Drug Administration 688 
(NAFDAC) by the SPHAR-TI trained participants in seven months are compared with the 689 
proportion of ICSRs submitted to NAFDAC by all the healthcare providers in Nigeria in seven 690 
months (3000 vs 805).  691 
4 = The number of Pharmacovigilance Committees activated by the participants before they were 692 
trained is compared with the number they activated after they were trained (0 vs 46). 693 
 694 
 695 
 696 
